
Sign up to save your podcasts
Or


Scientists at UC San Diego have developed a new AI platform called POLYGON that has the potential to revolutionize drug discovery. Unlike existing protocols, POLYGON can identify molecules with multiple targets, which is significant as multi-target drugs have the potential to deliver the same benefits as combination therapy, but with fewer side effects. To train POLYGON, researchers used a database of over a million known bioactive molecules, allowing it to generate new candidate drugs with specific properties. They synthesized 32 molecules that had strong predicted interactions with cancer-related proteins MEK1 and mTOR, suggesting they could potentially target both proteins as a cancer treatment.
By Dr. Tony Hoang4.6
99 ratings
Scientists at UC San Diego have developed a new AI platform called POLYGON that has the potential to revolutionize drug discovery. Unlike existing protocols, POLYGON can identify molecules with multiple targets, which is significant as multi-target drugs have the potential to deliver the same benefits as combination therapy, but with fewer side effects. To train POLYGON, researchers used a database of over a million known bioactive molecules, allowing it to generate new candidate drugs with specific properties. They synthesized 32 molecules that had strong predicted interactions with cancer-related proteins MEK1 and mTOR, suggesting they could potentially target both proteins as a cancer treatment.

91,091 Listeners

32,156 Listeners

229,089 Listeners

1,099 Listeners

341 Listeners

56,456 Listeners

153 Listeners

8,876 Listeners

2,040 Listeners

9,907 Listeners

507 Listeners

1,863 Listeners

79 Listeners

268 Listeners

4,230 Listeners